UConn and Alexion Pharmaceuticals are partnering to expand stem-cell research into combatting rare diseases. The collaboration will focus on the discovery and testing of therapeutic candidates to treat rare and disabling disorders for which there are currently no effective treatments.

The collaboration will build on research conducted by Dr. David J. Goldhamer, associate director of the UConn Stem Cell Institute.

“This collaboration targets unmet medical needs for patients while demonstrating the vitality of the life science community in Connecticut,” said Jeff Seemann, UConn’s vice president for research.